EICHOR
● Active Not Recruiting
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
Condition: Oropharyngeal Cancer · Sponsor: University of Birmingham
About this study
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (38)
| St Luke's Hospital | Dublin, Ireland | — |
| St James's Hospital | Dublin, Ireland | — |
| Aberdeen Royal Infirmary | Aberdeen, Aberdeen, United Kingdom | — |
| Bristol Haematology and Oncology Centre | Bristol, Bristol, United Kingdom | — |
| Velindre Cancer Centre | Cardiff, Cardiff, United Kingdom | — |
| Royal Devon and Exeter Hospital | Exeter, Devon, United Kingdom | — |
| Leicester Royal Infirmary | Leicester, East Midlands, United Kingdom | — |
| Castle Hill Hospital | Cottingham, East Yorkshire, United Kingdom | — |
| Western General Hospital | Edinburgh, Edinburgh, United Kingdom | — |
| Colchester General Hospital | Colchester, Essex, United Kingdom | — |
| Queen's Hospital | Romford, Essex, United Kingdom | — |
| Royal Preston Hospital | Preston, Lancashire, United Kingdom | — |
+ 26 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04116047